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Retinal neovascularizationRetinal neovascularization is themost common cause of moderate to severe vision loss in all age groups. Despite
the use of anti-VEGFA therapies, this complication continues to cause blindness, suggesting a role for additional
molecules in retinal neovascularization. Besides VEGFA and VEGFB, hypoxia induced VEGFC expression robustly.
Based on this ﬁnding, we tested the role of VEGFC in pathological retinal angiogenesis. VEGFC induced prolifer-
ation, migration, sprouting and tube formation of human retinal microvascular endothelial cells (HRMVECs)
and these responses require CREB-mediated DLL4 expression and NOTCH1 activation. Furthermore, down regu-
lation of VEGFC levels substantially reduced tip cell formation and retinal neovascularization in vivo. In addition,
we observed that CREB via modulating the DLL4-NOTCH1 signaling mediates VEGFC-induced tip cell formation
and retinal neovascularization. In regard to upstreammechanism, we found that down regulation of p38β levels
inhibited hypoxia-induced CREB-DLL4-NOTCH1 activation, tip cell formation, sprouting and retinal neovascular-
ization. Based on these ﬁndings, it may be suggested that VEGFC besides its role in the regulation of
lymphangiogenesis also plays a role in pathological retinal angiogenesis and this effect depends on p38β and
CREB-mediated activation of DLL4-NOTCH1 signaling.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Retinal neovascularization is themost common cause ofmoderate to
severe vision loss in all age groups; i.e., retinopathy of prematurity
(ROP) in children, diabetic retinopathy in adults and age-related
macular degeneration in the elderly (Andreoli and Miller, 2007; Chen
and Smith, 2007; Ferrara and Kerbel, 2005). These various retinal
neovascular pathologies, in turn, may cause vitreous hemorrhage, reti-
nal detachment and/or neovascular glaucoma affecting vision (Aiello
et al., 1994). A large body of evidence shows that vascular endothelial
growth factor A (VEGFA) is one of the major factors linked to the path-
ogenesis of proliferative retinopathy (Alon et al., 1995). TheVEGF family
consists of 7 structurally related molecules (VEGF-A through F and pla-
cental growth factor) that bind to 3 tyrosine kinase receptors (VEGFR1,
2 and 3)with different afﬁnities (Karkkainen and Petrova, 2000). VEGFA
has been the focus ofmany current anti-angiogenesis regimens as itwas
themost characterized angiogenic and permeability factor implicated in
various pathologies including retinal neovascularization (Kuiper et al.,
2008). However, the anti-VEGFA therapies have been observed to
have some deleterious effects such as an increase in the expression of
connective tissue growth factor (CTGF), which promotes a switchUniversity of Tennessee Health
SA.
. This is an open access article underfrom angiogenesis to ﬁbrosis (Kuiper et al., 2008). In addition, 82% of
the tractional retinal detachments (TRDs) were reported linked to
anti-VEGFA injections (Arevalo et al., 2008). Furthermore, besides
VEGFA, other molecules such as VEGFC and VEGFD have been reported
to play a role in angiogenesis and lymphangiogenesis via activation of
VEGFR2 and VEGFR3 (Achen et al., 1998; Cao et al., 1998). Although,
the initial studies have reported that the expression of VEGFR3 is
restricted to lymphatic endothelium (Jeltsch et al., 1997; Kaipainen
et al., 1995), it is now recognized that the VEGFC–VEGFR3 signaling
also modulates the branching morphogenesis of blood vessels
(Tammela et al., 2008). Despite these advances in our understanding
of the role of VEGFC in angiogenesis and lymphangiogenesis, its involve-
ment in pathological retinal angiogenesis is not explored.
The cyclic adenosine monophosphate (cAMP)-response element-
binding protein (CREB) is a transcription factor that belongs to the
basic leucine-zipper family and binds to a speciﬁc regulatory element
known as cAMP-response element (CREs) in the promoters of its target
genes and enhances their expression (Shaywitz and Greenberg, 1999).
CREB mediates hypoxia-induced expression of a number of genes,
including VEGFA and its receptors (Kang et al., 2014; Leonard et al.,
2008; Morishita et al., 1995; Wu et al., 2007). Many studies have also
demonstrated that VEGFA, FGF2 and hepatocyte growth factor by
phosphorylating increase CREB transcriptional transactivation activity
in endothelial cells (Abramovitch et al., 2004; Hoot et al., 2010;
Kottakis et al., 2011; Zhao et al., 2011). Furthermore, it has beenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tumor angiogenesis (Abramovitch et al., 2004). Despite these clues
linking CREB to the modulation of angiogenesis, its developmental or
pathological angiogenesis is not known. In the present study, we used
a mouse model of retinopathy to understand the role of CREB in patho-
logical retinal neovascularization. The mouse model of retinopathy
which involves an initial phase of hyperoxia-induced vessel loss, follow-
ed by a phase of hypoxia-induced pathological neovascularization
(Smith et al., 1994), allowed us to decipher the role of VEGFC and
CREB axis in pathological retinal neovascularization. Our results for
the ﬁrst time demonstrate that CREB by modulating DLL4–NOTCH1
signaling plays a crucial role in pathological retinal angiogenesis.
2. Materials and Methods
2.1. Reagents
Growth factor-reduced Matrigel (354,230) was obtained from BD
Biosciences (Bedford, MA). Recombinant human VEGFB167 (751-VE),
recombinant human VEGFC (2179-VC), recombinant human VEGFD
(622-VD) and anti-VEGFR3 (AF743) antibodies were bought from R &
D Systems (Minneapolis, MN). Anti-GFP (SC-9996), anti-JNK1/3
(SC-474), anti-β-tubulin (SC-9104), anti-VEGFA (SC-152), anti-VEGFB
(SC-80,442), anti-VEGFC (SC-130,289) and anti-VEGFD (SC-13,085)
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-pCREB (9198), anti-CREB (4820), anti-pJNK1 (9251)
and anti-pp38MAPK (9198) antibodies were obtained from Cell Signal-
ing Technology (Beverly, MA). Anti-NOTCH2 (07–1234) antibodies
were bought fromMillipore (Temecula, CA). Anti-CD31 (550,274) anti-
body was purchased from BD Pharmingen (Palo Alto, CA). Anti-DLL1
(ab84620), anti-DLL4 (ab7280), anti-Ki67 (ab15580), anti-NOTCH1
(ab52627) and anti-NOTCH4 (ab166605) antibodies were obtained
from Abcam (Cambridge, MA). Anti-NOTCH1 antibody (NB100-
78,486) was bought from Novus Biologicals (Littleton, CO). Thirty μ-
Dish 35 mm, low culture-inserts were purchased from ibidi (Munich,
Germany). EGM2 medium was purchased from Lonza (Basel,
Switzerland). Control nontargeting small interfering RNA (siRNA)
(D-001,810-10), human DLL4 siRNA (ON-TARGET plus SMARTpool
L-010,490-00), human NOTCH1 siRNA (ON-TARGET plus SMARTpool
L-007,771-00), mouse CREB siRNA (ON-TARGET plus SMARTpool L-
040,591-00), mouse DLL4 siRNA (ON-TARGET plus SMARTpool
L-045,947-00), mouse JNK1 siRNA (ON-TARGET plus SMARTpool L-
040,128-00), mouse p38MAPKβ siRNA (ON-TARGET plus SMARTpool
L-040,613-00), mouse NOTCH1 siRNA (ON-TARGET plus SMARTpool
L-041,110-00), mouse VEGFC siRNA (ON-TARGET plus SMARTpool
L-012,071-00) and anti-p38MAPKβ (PA5-14,425) antibodies were
obtained from Thermo Scientiﬁc (Chicago, IL). Cell Tracker Green
(C7025), Alexa Fluor 488-conjugated goat anti-rat immunoglobulin G,
Alexa Fluor 568-conjugated goat anti-rabbit immunoglobulin G,
Hoechst 33,342, isolectin B4-594, and Prolong Gold antifade reagent
were bought from Molecular Probes (Eugene, OR). Cytodex beads
(C3275) and thrombin (T8885) were purchased from SIGMA-ALDRICH
(St. Louis, MO). Bovine ﬁbrinogen (820,224) was purchased from MP
Biomedicals (Irvine, CA). [3H]-Thymidine (S. A. 20 Ci/mM)was obtained
from Perkin Elmer (Boston, MA).
2.2. Generation of Conditional Knockout Mice
To delete CREB in the postnatal vasculature, we interbred CREBﬂox/ﬂox
mice (Mantamadiotis et al., 2002) with transgenic mice expressing the
tamoxifen-inducible recombinase (CreERT2) under the control of the en-
dothelial Cdh5 promoter (Wang et al., 2010). CREBﬂox/−:Cdh5-CreERT2
mice were interbred with CREBﬂox/ﬂox to generate CREBﬂox/ﬂox:Cdh5-
CreERT2 litters. To induce Cre activity and genedeletion, two consecutive
intraperitoneal tamoxifen (Sigma-Aldrich, T5648; 2 mg/ml; generated
by dissolving in 10% ethanol and 90% corn oil) injections of 50 μl weregiven at P10 and P11 to generate endothelial speciﬁc deletion of CREB
(CREBiΔEC). The Animal Care and Use Committee of the University
of Tennessee Health Science Center, Memphis, TN, approved all the
experiments involving the use of animals.
2.3. Cell Culture
HRMVECs (ACBRI 181) were purchased from Applied Cell Biology
Research Institute (Kirkland,WA) and grown inmedium131 containing
microvascular growth supplements (MVGS), 10 μg/ml gentamycin, and
0.25 μg/ml amphotericin B. Cultures were maintained at 37°C in a
humidiﬁed 95% air and 5% CO2 atmosphere. HRMVECs with passage
numbers between 5 and 10 were synchronized by incubating in
medium 131 without MVGS for 24 h and used to perform the experi-
ments unless otherwise indicated.
2.4. Cell Migration
Cell migration was measured by wounding assay as described by
us previously (Singh et al., 2015). Brieﬂy, HRMVECs were plated at
2 × 105 cells/ml in each chamber of the ibidi culture-inserts, grown to
full conﬂuency and growth-arrested. Following a 12-h growth-
arresting period, the inserts were removed using sterile tweezers and
1 ml of medium 131 containing 5 mM hydroxyurea was added to the
culture dish. Cells were treated with and without VEGFC (100 ng/ml)
for 24 h and cell migration was observed under Nikon Eclipse TS100
microscopewith 10×/0.25magniﬁcation and the imageswere captured
with a CCD color camera (KP-D20AU; Hitachi, Ibaraki, Japan) using
Apple iMovie 7.1.4 software. The cell migration was expressed as per-
cent wound closure (total wound area at 0 h minus wound area at 24
h/total wound area at 0 h × 100).
2.5. DNA Synthesis
DNA synthesis was measured by [3H]-thymidine incorporation
using 3D ON-TOP assay (Lee et al., 2007). Brieﬂy, quiesced HRMVECs
were trypsinized to a single-cell suspension and 1 × 105 cells in 0.5 ml
of the medium were plated onto a matrigel-coated surface of a
24-well plate and VEGFC (100 ng/ml) or vehicle were added to theme-
dium. Cells were allowed to settle for 30 min at 37°C, following which
0.5 ml of medium containing 10% matrigel was added on top of the
cells. Six hours later, the cells were pulse-labeled with 1 μCi/ml of
[3H]-thymidine for 24 h, at which time cells were washed with cold
PBS, collected along with matrigel in 3 ml of 5 mM EDTA in cold PBS
into 15 ml centrifuge tubes. The tubes were kept on ice for 15 min to
allow the breakdown of matrigel. The cells were then added with 3 ml
of 20% (w/v) cold TCA and vortexed vigorously to lyse the cells. The
cell mixture was allowed to remain on ice for 30 min and then passed
through a GF/F glass microﬁber ﬁlter. The ﬁlter was washed once with
5% cold TCA and once with cold ethanol, dried, placed in a liquid scintil-
lation vial containing the scintillation ﬂuid and the radioactivity was
measured in a liquid scintillation counter (Beckman LS 3801). DNA syn-
thesis was expressed as counts/min/well.
2.6. Sprouting Assay
Three-dimensional sprouting was performed according to a previ-
ously described protocol (Nakatsu and Hughes, 2008). Brieﬂy, the
HRMVECs transfected with the indicated siRNA or transduced with
the indicated adenovirus were coated on Cytodex beads and allowed
to attach overnight. The beads were embedded in ﬁbrin gels and ﬁbro-
blasts were added onto the top of the gels. Sprouting was examined on
day 3 under Zeiss inverted ﬂuorescence microscope (Carl Zeiss AxioVi-
sion Observer.Z1; original magniﬁcation ×10/NA 0.45) and the ﬂuores-
cence images were captured using Zeiss AxioCamMRm camera and the
microscope operating and image analysis software AxioVision 4.7.2
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number of sprouts/bead.2.7. Tube Formation
Tube formation was measured as described previously (Singh et al.,
2013). Quiescent HRMVECs were placed in 24-well culture dishes
(Costar; Corning) coated with growth factor-reduced Matrigel (BD Bio-
sciences). Vehicle or VEGFCwere added and the cells were incubated at
37°C for 6 h. When siRNA or adenoviral vectors were used, cells were
transfected with the indicated siRNA or transduced with the indicated
adenovirus and quiesced before they were subjected to tube formation
assay. After 6 h of incubation, tube formation was observed under an
inverted microscope (Eclipse TS100; Nikon, Tokyo, Japan) and the im-
ages were captured with a CCD color camera (KP-D20AU; Hitachi,
Ibaraki, Japan) using Apple iMovie 7.1.4 software. The tube length was
calculated usingNIH ImageJ version 1.43 and expressed inmicrometers.2.8. Western Blotting
Cell or tissue extracts containing an equal amount of protein were
resolved by electrophoresis on 0.1% (weight/volume [w/v]) sodium
dodecyl sulfate and 10% (w/v) polyacrylamide gels. The proteins were
transferred electrophoretically to a nitrocellulose membrane. After
blocking in either 5% (w/v) nonfat dry milk or bovine serum albumin,
the membrane was probed with the appropriate primary antibodies
followed by incubation with horseradish-peroxidase-conjugated
secondary antibodies. The antigen-antibody complexes were detected
using an enhanced chemiluminescence detection reagent kit (Amersham
Biosciences).2.9. Transfections
HRMVECs were transfected with control or target siRNA molecules
at a ﬁnal concentration of 100 nM using Lipofectamine 2000 transfec-
tion reagent according to the manufacturer's instructions. After
transfections, cells were growth-arrested in MVGS-free medium 131
for 24 h and used as required.2.10. Oxygen-Induced Retinopathy (OIR)
OIR was performed as described by Smith et al. (1994) and quanti-
ﬁed according to the method of Connor et al. (2009). C57BL/6 mice
pups (P7) with dams were exposed to 75% oxygen for 5 days and then
returned to room air at P12. Mice pups of the same age kept at room
air were used as controls. Mice pups were sacriﬁced at P17 and eyes
were enucleated and ﬁxed in 4% (v/v) paraformaldehyde for 1 h at
room temperature. Retinas were isolated, stained with isolectin B4,
ﬂat mounted, placed under a coverslip, and examined by a Zeiss
inverted ﬂuorescence microscope (Axio Observer.Z1). Retinal vascula-
ture was quantiﬁed by calculating the ratio of ﬂuorescence intensity to
total retinal area. Retinal neovascularization was quantiﬁed by ﬁrst
setting a scale with a tolerance point of 50 based on the ﬂuorescence
intensity in the screenshot using Nikon NIS-Elements software version
AR 3.1. Neovascularity was highlighted in red and then quantiﬁed by
dividing the ﬂuorescence intensity in the highlighted area by the total
ﬂuorescence intensity in the screenshot (n = 6 eyes).2.11. Intravitreal Injections
After exposure to hyperoxia, pups were administered with
scrambled, or the indicated siRNA at 1 μg/0.5 μl/eye) by intravitreal
injections using a 33G needle.2.12. Immunoﬂuorescence Staining
After hyperoxia, mouse pups were returned to room air for 3 days,
after which time they were sacriﬁced, eyes enucleated and ﬁxed in
optimal cutting temperature compound, and 8-μm cryosections were
prepared from the central part of the retina. To identify proliferating
ECs, after blocking in normal goat serum, the cryosections were probed
with rabbit anti-mouse Ki67 antibodies (1:100) and rat anti-mouse
CD31 antibodies (1:100) followed by incubation with Alexa Fluor
568-conjugated goat anti-rabbit and Alexa Fluor 488-conjugated goat
anti-rat secondary antibodies. The sections were observed under Zeiss
invertedmicroscope (AxioObserver.Z1; type, LDplan-Neoﬂuar; original
magniﬁcation X40/NA 0.6 or type, plan-Apochromat; original magniﬁ-
cation X10/NA 0.45) and the ﬂuorescence images were captured by
Zeiss AxioCam MRm camera using the microscope operating and
image analysis software AxioVision 4.7.2 (Carl Zeiss Imaging Solutions
GmbH). The retinal EC proliferation was quantiﬁed by counting Ki67-
and CD31-positive cells that extended anterior to the inner limiting
membrane per section (n = 6 eyes, 3 sections/eye).
2.13. DLL4 Promoter Cloning
Using HRMVEC genomic DNA as a template, DLL4 promoter
fragment from−2210 nucleotides (nt) to+78 ntwas ampliﬁed by po-
lymerase chain reaction using a forward primer, 5′-GAGCTCCTGCCCGG
TTGGACTGGGGA-3′ incorporating a SacI restriction enzyme site at the
5′-end and a reverse primer, 5′- AGATCTACGGAGTCTTGCTCTGTCAC
TCA-3′ incorporating BglII restriction site at the 5′-end. The resulting
~2.2 kb PCR product was digested with SacI and BglII and cloned into
SacI and BglII sites of the pGL3 basic vector (Promega) to yield pGL3-
hDLL4 (2.2 kb). To generate 5′-truncated promoter fragment starting
from−605 nt, forward primer, 5′-GAGCTCACCTGGTTCCTGCTCATTCT
CTTCC-3′, and reverse primer, hDLL4-R, 5′-AGATCTACGGAGTCTTGCTC
TGTCACTCA-3′, were used in the PCR. The PCR products were digested
with SacI and BglII and cloned into SacI and BglIII sites of the pGL3
basic vector to yield pGL3-hDLL4 (0.68 kb). The underlined regions
are SacI and BglII sites in both the forward and the reverse primers, re-
spectively. Site-directed mutations within the CREB-binding element at
−193 nt were introduced by using the QuickChange site-directed mu-
tagenesis kit according tomanufacturer's instructions and using the fol-
lowing primers: forward, 5′-GTGAGTTTCCCTGGCAGGACCTCCGTCAGTT
CCAGTTGTGTTG-3′ and reverse, 5′-CAACACAACTGGAACTGACGGAGG
TCCTGCCAGGGAAACTCAC-3′ to yield pGL3-hDLL4m. The boldface
letters indicate the mutated bases. Clones were veriﬁed by DNA
sequencing using pGL3 vector-speciﬁc primers.
2.14. Luciferase Assay
HRMVECs cells were transfected with pGL3 empty vector or pGL3-
hDLL4 (2.2 kb and 0.68 kb) promoter constructs with and without the
indicated mutations using Lipofectamine 2000 transfection reagent.
After growth arrest in serum-free medium for 12 h, cells were treated
with and without VEGFC (100 ng/ml) for 4 h, washed with cold PBS,
and lysed in 200 μl of lysis buffer. The cell extracts were cleared by cen-
trifugation at 12,000 rpm for 2 min at 4°C. The supernatants were
assayed for luciferase activity using a luciferase assay system (Promega)
and a single tube luminometer (TD20/20; Turner Designs, Sunnyvale,
CA) and expressed as relative luciferase units.
2.15. Chromatin Immunprecipitation (ChIP) Assay
ChIP assay was performed on HRMVECs with and without the
indicated treatments using a kit and following the supplier′s protocol
(Upstate Biotechnology Inc., Lake Placid, NY). CREB–DNA complexes
were immunoprecipitated using anti-CREB antibodies. Preimmune
mouse serum was used as a negative control. The immunoprecipitated
Fig. 1.CREBmediatesVEGFC-induced angiogenic events. A. C57BL/6mice pups after exposure to 75% oxygen fromP7 to P12were returned to roomair to develop the relativehypoxia. Eyes
frompups left in normoxia or at various time periods of hypoxiawere enucleated, retinas isolated and extractswere prepared. An equal amount of protein fromnormoxic and various time
periods of hypoxic retinal extracts was analyzed by Western blotting for VEGFA, VEGFB, VEGFC and VEGFD levels using their speciﬁc antibodies and normalized to β-tubulin. B–D.
Quiescent HRMVECs were treated with and without VEGFC (100 ng/ml) and DNA synthesis (B), migration (C), or tube formation (D) were measured. E. An equal amount of protein
from control and the indicated time periods of VEGFC (100 ng/ml)-treated HRMVECs was analyzed by Western blotting for pCREB levels using its phospho-speciﬁc antibodies and nor-
malized to CREB. F. Cells were transduced with Ad-GFP or Ad-KCREB (40 moi) and 48 h later cell extracts were prepared and analyzed for over expression of GFP or KCREB by Western
blotting using their speciﬁc antibodies and normalized to β-tubulin. G–I. All the conditions were the same as in panel F except that after transduction with the adenovirus, cells were
quiesced and subjected to VEGFC (100 ng/ml)-induced DNA synthesis (G), migration (H), or tube formation (I). J. All the conditions were the same as in panel F except that after trans-
duction, cells were labeled with Cell Tracker Green, coated onto Cytodex beads, embedded in a 3D-ﬁbrin gel in EGM2 medium for 3 days and sprouts were observed under ﬂuorescent
microscope. The images were captured using MRm camera. The bar graphs represent quantitative analysis of three independent experiments. The values are presented as Mean ± SD.
* p b 0.01 vs control, normoxia or Ad-GFP; ** p b 0.01 vs Ad-GFP + VEGFC. Scale bar represents 50 μm.
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Fig. 2. VEGFCmediates hypoxia-induced retinal neovascularization. A. After exposure to 75% oxygen from P7 to P12, pupswere returned to room air to develop the relative hypoxia. Pups
were administered intravitreallywith 1 μg/0.5 μl/eye of control or VEGFC siRNA at P12 and P13 and at P15 the retinas were isolated and either tissue extracts were prepared and analyzed
for VEGFC levels byWestern blottingusing its speciﬁc antibody and normalized toβ-tubulin orﬁxed, cross-sectionsmade and stained by immunoﬂuorescence for CD31 andKi67. The right
column shows the highermagniﬁcation (40×) of the areas selected by rectangular boxes in the left column images. B. Retinal EC proliferationwasmeasured by counting CD31- and Ki67-
positive cells that extended anterior to the inner limitingmembrane per section (n=6 eyes, 3 sections/eye). C. All the conditionswere the same as in panel A except that control or VEGFC
siRNAswere injected intravitreally at P12, P13, and P15 and at P17 the retinas were isolated, stained with isolectin B4, ﬂat mounts weremade and examined for EC ﬁlopodia formation at
40× magniﬁcation. D. All the conditions were the same as in panel A except that the sections were stained for CD31, VEGFR3 and DAPI. E. All the conditions were the same as in panel C
except that retinal neovascularizationwasmeasured at 2.5×magniﬁcation. Retinal vascularization is shown in the ﬁrst column. Neovascularization is highlighted in red in the second col-
umn. The third row shows the selected rectangular areas of the images in the ﬁrst column under 10× magniﬁcation. F & G. Retinal neovascularization (F) and avascular area (G) were
determined as described in “Materials and Methods.” The bar graphs represent quantitative analysis of three blots or 6 retinas. The values are presented as Mean ± SD. * p b 0.01 vs
normoxia + control siRNA; ** p b 0.01 vs hypoxia + control siRNA. Scale bar represents 50 μm and 20 μm in panel A, far left column and far right column, respectively, 20 μm in panels
C & D, 300 μm and 50 μm in panel E, far left column and far right column, respectively.
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using QIAquick columns (Cat. No. 28,104, Qiagen, Valenica, CA), and
used as a template for PCR ampliﬁcation with primers, forward,
5′-CCATTTCTACCTGTTGAAAT-3′, and reverse, 5′- ATGACCAGTGCAGT
CAACCA-3,′ that would amplify a 220 bp fragment encompassing the
CREB-binding site at−193 nt and used as a template for PCR ampliﬁca-
tion with primers, forward, 5′-TTCCTTATCTTCATCCTA-3′, and reverse,
5′- ATGACCAGTGCAGTCAACCA-3 that would amplify 106 bp fragment
encompassing the CREB binding site at −193 nt. The resulting PCR
products were resolved on 1.8% agarose gels and stained with ethidium
bromide and the images were captured using a Kodak In Vivo Imaging
System. For quantiﬁcation, the ChiP DNA was also subjected to qPCR
using the same primers on 7300 Real-Time PCR Systems (Applied
Biosystems) using SYBR Green PCR Master Mix (Cat. No. 4,309,155,
Applied Biosystems) with the following conditions: 95°C for 10 min
followed by 40 cycles at 95°C for 15 s with extension at 60°C for
1 min. Both IgG and anti-CREB–DNA Ct values were normalized to
input DNA Ct values to obtain ΔCt values. Then ΔΔCt values were
calculated by subtracting the ΔCt values of negative controls from the
experimental ΔCt values. The fold enrichment of CREB-bound DLL4
promoter is calculated by using 2(−ΔΔCt).
2.16. Electrophoretic Mobility Shift Assay
Nuclear extracts of HRMVECs with and without appropriate
treatments were prepared as described previously (Potula et al.,
2009). The protein content of the nuclear extracts was determined
using a micro-BCA method. Biotin-labeled double-stranded oligonucle-
otides encompassing CREB-binding element at−193 nt (5′- TCCCTGGC
AGGACTGACGTCAGTTCCAG-3′) and its complementary sequence was
used as a probe. Brieﬂy, 5 μg of nuclear extract was incubated in a bind-
ing buffer with 2.5 nmole biotin-labeled probe and 2 μg poly dI:dC for
30 min at room temperature in 20 μl binding reaction buffer (10 mM
Tris–HCl, pH 7.9, 50 mM KCl, 1 mM DTT, 15% glycerol). The
DNA-protein complexes were analyzed by electrophoresis on 6%
polyacrylamide gel and visualized by chemiluminescence. To perform
a supershift electrophoretic mobility shift assay, the complete reaction
mix was incubated with the indicated antibodies for 1 h on ice before
separating it by electrophoresis. Normal serum was used as a negative
control.
2.17. Statistics
All experiments were repeated 3 times and data are presented as
mean ± standard deviation (SD). The treatment effects were analyzed
by One-way ANOVA and Bonferroni multiple comparison test and p
values b0.05 were considered statistically signiﬁcant. In the case of
ChIP, EMSA, supershift EMSA, Western blots, immunoﬂuorescence &
ﬂuorescence staining, one data set is presented.Fig. 3. CREB mediates hypoxia-induced retinal neovascularization. A. An equal amount of prot
Western blotting for pCREB levels using its phospho-speciﬁc antibody and normalized to CR
and at P15 the retinas were isolated, ﬁxed, cross-sections were made and stained by immunoﬂ
that pups were administered intravitreally with 1 μg/0.5 μl/eye of control or VEGFC siRNA at P1
amount of protein fromnormoxic and hypoxic retinal extracts was analyzed byWestern blottin
β-tubulin levels to show the effects of the siRNA on its target and off-target molecules, respectiv
intravitreally with 1 μg/0.5 μl/eye of control or VEGFC siRNA at P12 and P13 and that at P15 th
described in Fig. 2, panel A. The right column shows the higher magniﬁcation (40×) of the area
liferation was measured by counting CD31- and Ki67-positive cells that extended anterior to th
were the same as in panel D except that control or CREB siRNAswere injected intravitreally at P
were made and examined for EC ﬁlopodia formation at 40× magniﬁcation. G. All the condition
DAPI. H. All the conditions were the same as in panel F except that retinal neovascularization w
Neovascularization is highlighted in red in the second column. The third row shows the select
& J. Retinal neovascularization (I) and avascular areas (J) were determined as described in “Mat
inas. The values are presented asMean± SD. * p b 0.01 vs normoxia or normoxia+ control siRN
represents 50 μm and 20 μm in panels B & D, far left column and far right column, respectively,
respectively.3. Results
3.1. CREB Mediates VEGFC-Induced Sprouting and Tube Formation In vitro
and Hypoxia-Induced Retinal Neovascularization In vivo
Current anti-angiogenic therapies are focusedmostly onVEGFAneu-
tralization or blockade of its signaling. However, a number of patients
suffering from age-related macular degeneration or cancer do not re-
spond to anti-VEGFA therapies (Jubb and Harris, 2010; Lux et al.,
2007). Anti-VEGFA therapies have also been reported to cause tractional
retinal detachments (Arevalo et al., 2008; Kuiper et al., 2008). Due to
these reasons, we examined for VEGFA-related molecules that may in-
ﬂuence angiogenesis and found that hypoxia induces the expression
of VEGFC as robustly as VEGFA or VEGFB and VEGFD to a modest level
in mouse retina (Fig. 1A). As we have previously reported a role for
both VEGFA and VEGFB in retinal neovascularization (Singh et al.,
2013) and hypoxia induces VEGFC as robustly as VEGFA, in the present
study we have focused on the role of VEGFC in retinal neovasculariza-
tion. VEGFC stimulated proliferation, migration and tube formation of
HRMVECs (Fig. 1B-D). Since a role for CREB in tumor angiogenesis
has been demonstrated (Abramovitch et al., 2004) and as nothing is
knownon its role in developmental or pathological retinal angiogenesis,
we asked the question whether VEGFC activates this leucine-zipper
transcriptional factor in mediating HRMVEC proliferation, migration
and tube formation. VEGFC induced the phosphorylation of CREB
in a time-dependent manner in HRMVECs (Fig. 1E). In addition,
adenoviral-mediated expression of KCREB, the dominant negative mu-
tant of CREB, attenuated VEGFC-induced proliferation, migration and
tube formation of HRMVECs (Fig. 1F–I). Since sprouting is required for
tubulogenesis,we also tested the effect of VEGFC onHRMVEC sprouting.
VEGFC induced HRMVEC sprouting in a manner that is also sensitive to
inhibition of CREB (Fig. 1J). Together, these data demonstrate that
VEGFC induces HRMVEC proliferation, migration, sprouting and
tubulogenesis and CREBmediates these effects. To validate these obser-
vations in vivo, we used oxygen-induced retinopathy (OIR) model.
VEGFC down regulation using its siRNA inhibited hypoxia-induced ret-
inal EC proliferation as observed by a decrease in the number of CD31
and Ki67-positive cells, the former being a marker for ECs and the latter
being a marker for proliferating cells (Fig. 2A & B). In addition, blockade
of VEGFC expression attenuated hypoxia-induced retinal EC ﬁlopodia
formation suggesting its possible role in tip cell formation (Fig. 2C).
Down regulation of VEGFC levels also attenuated hypoxia-induced
expression of VEGFR3 (Fig. 2D), a marker for tip cells (Nicoli et al.,
2012). Consistent with these observations, down regulation of VEGFC
inhibited neovascularization with a reduction in tufts and anastomoses
(Fig. 2E–G). Since phosphorylation at Ser133 is required for CREB activa-
tion (Arany et al., 1994; Chrivia et al., 1993), we next examined the ef-
fect of hypoxia on CREB phosphorylation. Hypoxia induced CREB
phosphorylation in a time-dependent manner in mouse retina with
maximum effect at 24 h and declining thereafter (Fig. 3A). Doubleein from normoxic and various time periods of hypoxic retinal extracts were analyzed by
EB. B. Following exposure to hyperoxia from P7 to P12, pups were returned to room air
uorescence for CD31 and pCREB. C. All the conditions were the same as in panel B except
0 and P11 and at P13 the retinas were isolated and tissue extracts were prepared. An equal
g for pCREB and CREB levels as described in panel A and the blotwas reprobed for VEGFC or
ely. D. All the conditions were the same as in panel C except that pups were administered
e retinas were isolated and processed for CD31 and Ki67 immunoﬂuorescence staining as
s selected by rectangular boxes in the images shown in the left column. E. Retinal EC pro-
e inner limiting membrane per section (n = 6 eyes, 3 sections/eye). F. All the conditions
12, P13, and P15 and at P17 the retinas were isolated, stainedwith isolectin B4, ﬂatmounts
s were the same as in panel D except that the sections were stained for CD31, VEGFR3 and
as measured at 2.5× magniﬁcation. Retinal vascularization is shown in the ﬁrst column.
ed rectangular areas of the images shown in the ﬁrst column under 10× magniﬁcation. I
erials and Methods.” The bar graphs represent quantitative analysis of three blots or 6 ret-
A; ** p b 0.01 vs hypoxia+ control siRNA; § p b 0.05 vs hypoxia+ control siRNA. Scale bar
20 μm in panels F & G, 300 μm and 50 μm in panel H, far left column and far right column,
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1775N.K. Singh et al. / EBioMedicine 2 (2015) 1767–1784immunoﬂuorescence staining for CD31 and pCREB revealed that hypox-
ia induces CREB phosphorylationmostly in retinal ECs (Fig. 3B). In addi-
tion, down regulation of VEGFC substantially blocked hypoxia-induced
CREB phosphorylation (Fig. 3C). Depletion of CREB levels using its
siRNA also attenuated retinal EC proliferation, ﬁlopodia formation,
VEGFR3 expression and neovascularization with more extensive vaso-
obliteration (Fig. 3D–J).3.2. CREBModulates VEGFC-Induced Activation of DLL4-NOTCH1 Signaling
Previously, it has been reported that VEGFC activates VEGFR3 in tip
cells to activate NOTCH signaling in the neighboring ECs leading to
their phenotypic conversion to stalk cells (Tammela et al., 2008). Our
data demonstrates that VEGFC mediates CREB activation both in vitro
and in vivo. In addition, blockade of CREB activation led to a decrease
in VEGFC-induced HRMVEC sprouting and tubulogenesis in vitro and
retinal EC proliferation, ﬁlopodia formation, VEGFR3 expression and
neovascularization in vivo. Based on these ﬁndings, we hypothesized
that VEGFC might be activating NOTCH signaling requiring CREB. To
test this,we have studied the time course effect of VEGFC onNOTCH sig-
naling in HRMVECs. VEGFC while having no major effect on the steady
state levels of DLL1, Jagged1, cleaved NOTCH2 and cleaved NOTCH4, in-
creased the expression of DLL4 and augmented the production of
cleaved NOTCH1 (cNOTCH1) levels in HRMVECs (Fig. 4A). In order to
ﬁnd the link between CREB and DLL4-NOTCH1 signaling, we tested
the effect of KCREB on VEGFC-induced DLL4 expression and cleaved
NOTCH1 levels. Adenoviral-mediated expression of KCREB blocked
VEGFC-induced DLL4 expression and cleaved NOTCH1 production in
HRMVECs (Fig. 4B). As VEGFA also activates CREB (Evans et al., 2010),
we wanted to ﬁnd whether VEGFA has any effect on DLL4 expression
and cNOTCH1 levels in HRMVECs. VEGFA while stimulating CREB phos-
phorylation, had no apparent effect on DLL4 expression or cNOTCH1
levels (Fig. 4C). To ﬁnd a link between DLL4 and cNOTCH1, we tested
the effect of DLL4 siRNA on VEGFC-induced cNOTCH1 levels. Down reg-
ulation of DLL4 attenuated VEGFC-induced cNOTCH1 levels (Fig. 4D).
Having found that CREB mediates VEGFC-induced DLL4-NOTCH1 sig-
naling, we next investigated the effects of DLL4 and NOTCH1 on
VEGFC-induced tube formation and sprouting. Knockdown of either
DLL4 or NOTCH1 levels with their respective siRNA molecules reduced
VEGFC-induced proliferation, migration, tube formation and sprouting
(Fig. 4E–I). Together, these data provide compelling evidence that
CREBmediates VEGFC-inducedDLL4 expression andNOTCH1 activation
leading to EC proliferation, migration, sprouting and tubulogenesis.
To understand the molecular mechanisms by which CREB regulates
VEGFC-induced DLL4 expression, we cloned a ~ 2.21 kb human DLL4
promoter and identiﬁed two putative CREB binding sites, one at
−193 nt and the other at−2026 nt by TRANSFAC analysis (Fig. 5A).
The full-length 2.2 kb and a truncated region consisting of from
−605 nt to +78 nt DLL4 promoter sequences were sub-cloned into
pGL3 basic vector, transfected HRMVECs, treated with and without
VEGFC for 4 h and the luciferase activity was measured. VEGFC induced
a 6-fold increase in the luciferase activity with both full-length pGL3-Fig. 4.DLL4 and NOTCH1mediate VEGFC-induced angiogenic events. A. An equal amount of pro
analyzed byWestern blotting for DLL1, DLL4, Jagged1, NOTCH1, NOTCH2 andNOTCH4 levels usi
ducedwith Ad-GFP or Ad-KCREB (40moi), growth-arrested, treatedwith andwithout VEGFC (1
DLL4 and NOTCH1 levels using their speciﬁc antibodies and the blot was sequentially reprobe
C. Anequal amount of protein from control andvarious timeperiods of VEGFA (40 ng/ml)-treate
using their speciﬁc antibodies and theDLL4blotwasnormalized toβ-tubulin. D.HRMVECswere
(100 ng/ml) for 2 h, cell extracts were prepared and analyzed by Western blotting for NOTCH1
were transfected with control, DLL4 or NOTCH1 siRNA and 48 h later either cell extracts were p
antibodies and normalized toβ-tubulin. F–H.All the conditionswere the same as in panel E exce
DNA synthesis (F), migration (G), or tube formation (H). I. All the conditionswere the same as in
in Fig. 1, panel J. The bar graphs represent quantitative analysis of 3 independent experiments. T
VEGFC. Scale bar represents 50 μm in panel F.hDLL4 (2.2 kb) and truncated pGL3-hDLL4 (0.68 kb) promoter con-
structs (Fig. 5B), suggesting that CREB element at−193 nt is sufﬁcient
for VEGFC-induced DLL4 promoter activity. To conﬁrm these observa-
tions, we also studied a time course effect of VEGFC on CREB–DNA-
binding activity by EMSA using CREB binding element at−193 nt as a
biotin-labeled double-stranded oligonucleotide probe. VEGFC induced
CREB–DNA-binding activity in a time-dependent manner with near
maximum effect at 2 h (Fig. 5C). Furthermore, super-shift EMSA using
anti-CREB antibodies conﬁrmed the presence of CREB in DLL4 promoter
DNA-protein complexes (Fig. 5C). In addition, ChIP analysis revealed a
time-dependent binding of CREB to DLL4 promoter in response to
VEGFC in vivo as well (Fig. 5D). Supporting these observations, site-
directedmutagenesis of CREB element at−193 nt signiﬁcantly reduced
VEGFC-induced DLL4 promoter activity (Fig. 5E).
To test whether CREB modulates DLL4–NOTCH1 signaling in vivo,
we studied the effect of hypoxia on DLL4 expression and cNOTCH1
generation. Hypoxia with little or no effect on DLL1 and Jagged1 levels
induced DLL4 expression in the mouse retina (Fig. 6A). We also
observed that hypoxia increases cNOTCH1 production with little or no
effect on cNOTCH2 or cNOTCH4 levels (Fig. 6A). Furthermore, depletion
of either VEGFC or CREB levels attenuated hypoxia-induced DLL4
expression and cNOTCH1 generation (Fig. 6B). Next, we studied the
role of DLL4–NOTCH1 signaling in retinal neovascularization. Down reg-
ulation of either DLL4 or NOTCH1 levels resulted in decreased retinal EC
proliferation, ﬁlopodia formation and VEGFR3 expression (Fig. 6C–F).
Consistent with these observations, depletion of DLL4 or NOTCH1 levels
also caused a marked decrease in vessel anastomoses and retinal
neovascularization with more extensive vaso-obliteration as compared
to controls (Fig. 6G–I). These results imply that blockade of
DLL4–NOTCH1 signaling decreases tip cell formation and as a result of
this affects stalk cell differentiation, thereby decreasing the vessel
anastomoses.3.3. Conditional Deletion of CREB Suppresses DLL4-NOTCH1 Activation and
Retinal Neovascularization
To obtain additional support on the role of CREB in NOTCH1 activa-
tion and retinal neovascularization, we investigated the consequences
of homozygous endothelial-speciﬁc loss of CREB during OIR. EC-
speciﬁc deletion of CREB was achieved in CREBﬂox/ﬂox:Cdh5-CreERT2
mice by 2 consecutive intraperitoneal injections of tamoxifen on P10
and P11 (Fig. 7A). Cdh5-CreERT2mice injectedwith two consecutive in-
jections of tamoxifen were used as WT control. As shown in Fig. 7A,
some residual CREBwas detected in retinal extracts byWestern blotting
when Cre was induced in CREBﬂox/ﬂox:Cdh5-CreERT2 (CREBiΔEC) mice,
presumably due to other cell types such as retinal muller glial cell
CREB. At P13, CREBiΔEC pups exhibited a signiﬁcant decrease in
hypoxia-induced DLL4 expression and cNOTCH1 production (Fig. 7B),
indicating that CREB contributes to activation of NOTCH1 signaling in
hypoxic retina. CREBiΔEC pups also showed a signiﬁcant decrease in ret-
inal EC proliferation, ﬁlopodia formation and neovascularization with
extensive vaso-obliteration as compared to WT pups (Fig. 7C–H).tein from control and various time periods of VEGFC (100 ng/ml)-treated HRMVECswere
ng their speciﬁc antibodies. The DLL4 blotwas normalized to β-tubulin. B. Cells were trans-
00 ng/ml) for the indicated time periods and cell extracts were prepared and analyzed for
d for CREB, and β-tubulin levels to show the overexpression of KCREB and normalization.
dHRMVECswere analyzed byWesternblotting for pCREB, CREB, DLL4 and cNOTCH1 levels
transfectedwith control, or DLL4 siRNA, growth-arrested, treatedwith andwithoutVEGFC
and DLL4 levels using their speciﬁc antibodies and normalized to β-tubulin. E. HRMVECs
repared and analyzed byWestern blotting for DLL4 and NOTCH1 levels using their speciﬁc
pt that after transfection, cellswere quiesced and subjected to VEGFC (100 ng/ml)-induced
panel E except that after transfection cells were subjected to sprouting assay as described
he values are presented asMean± SD. * p b 0.01 vs control; ** p b 0.01 vs control siRNA+
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signaling in modulating pathological retinal neovascularization.
3.4. p38MAPK Mediates VEGFC-Induced CREB-DLL4-NOTCH1 Activation in
Retinal Neovascularization
Since CREB is activated by phosphorylation, we next examined for
the upstream signaling events in VEGFC-induced CREB activation.
VEGFC stimulated the phosphorylation of JNK1 and p38MAPK in a
time-dependent manner in HRMVECs (Fig. 8A). While dominant
negativemutant-mediated blockade of JNK1 activation had no effect, in-
hibition of p38MAPKβ by its dominant negative mutant suppressed
VEGFC-induced CREB phosphorylation in HRMVECs (Fig. 8B). Because
p38MAPKβ is involved in VEGFC-induced CREB activation, we further
examined for its role in VEGFC-induced DLL4 expression and cNOTCH1
levels. Blockade of p38MAPKβ activation inhibited VEGFC-inducedDLL4
expression and cNOTCH1 levels (Fig. 8C). Furthermore, inhibition of
p38MAPKβ also attenuated VEGFC-induced proliferation, migration,
tube formation and sprouting of HRMVECs (Fig. 8D–G). Having found
that p38MAPKβ mediates VEGFC-induced CREB–DLL4–NOTCH1
signaling, we next studied its role in hypoxia-induced retinal neovascu-
larization. Hypoxia induced p38MAPK activation as measured by its in-
creased phosphorylation (Fig. 9A). In addition, siRNA-mediated down
regulation of VEGFC levels attenuated hypoxia-induced p38MAPK
phosphorylation suggesting that VEGFC mediates hypoxia-induced
p38MAPK activation (Fig. 9B). Consistent with these observations,
down regulation of p38MAPKβ levels inhibited hypoxia-induced CREB
phosphorylation, DLL4 expression, cNOTCH1 levels, retinal EC prolifera-
tion, ﬁlopodia formation, VEGFR3 expression and neovascularization
(Fig. 9C–I).
4. Discussion
Hypoxia and hypoxia-inducible factors are important cues in the
modulation of retinal neovascularization (Arjamaa and Nikinmaa,
2006; Gariano and Gardner, 2005). It should be pointed out that hypox-
ia by itself provokes a constellation of signaling events that promote an-
giogenesis (Konisti et al., 2012; Semenza, 2003). Although a large body
of evidence shows that VEGFA plays a major role in pathological retinal
neovascularization (Carmeliet et al., 1996; Ferrara et al., 1996), the anti-
VEGFA therapies have failed in the reduction of the overall severity of
the disease and a number of patients suffering fromage-relatedmacular
degeneration or cancer do not respond to these regimens (Jubb and
Harris, 2010; Lux et al., 2007). In this regard, to understand the role of
other molecules in the modulation of pathological retinal angiogenesis,
we studied the capacity of VEGFA-related molecules. We found that
hypoxia induces the expression of VEGFC as potently as VEGFA in the
retina. Interestingly, VEGFC expression was also found in angiogenic ECs
during retinal development (Tammela et al., 2008). VEGFC induces the
proliferation, migration, sprouting and tube formation of HRMVECs, the
ﬁndings suggesting its role in retinal angiogenesis. As CREB mediates
hypoxia-induced expression of a number of growth factors (Kang et al.,
2014; Leonard et al., 2008; Morishita et al., 1995; Wu et al., 2007) andFig. 5. CREB is required for VEGFC-induced DLL4 promoter activity. A. DLL4 promoter encompas
highlighted in bold italic letters is shown. B. The full-length (from−2210nt to+78nt) and a tru
vector yielding pGL3-hDLL4 (2.28 kb) and pGL3-hDLL4 (0.68 kb) plasmids. HRMVECs were tra
plasmid DNAs, growth-arrested, treated with vehicle or VEGFC for 4 h and the luciferase acti
VEGFC (100 ng/ml)-treated cells were analyzed by EMSA for CREB binding using CREB-bindin
2 h of VEGFC (100 ng/ml)-treated cells were analyzed by supershift EMSA using normal IgG or
cells were analyzed for CREB binding to DLL4 promoter by ChIP assay using two sets of prime
at−193 nt. The data in the bar graph in panel D represents the qPCR of 106 bp region of CREB
(0.68 kb) promoter plasmid DNA with and without the CREB-binding site mutated (TGA was
and the luciferase activity was measured. The bar graphs represent quantitative analysis of t
** p b 0.01 vs pGL3-hDLL4 (0.68 kb) + VEGFC.its activity potentiates tumor angiogenesis (Abramovitch et al., 2004),
we explored its role in VEGFC-induced HRMVEC proliferation, migration,
sprouting and tube formation. Our results indicate that VEGFC stimulates
CREB activation in HRMVECs. In addition, blockade of CREB activation
by its dominant negativemutant bluntedVEGFC-inducedHRMVECprolif-
eration,migration, sprouting and tube formation. Theseﬁndings infer that
CREBmediates VEGFC-induced angiogenic events in HRMVECs. Although
the involvement of CREB in tumor angiogenesis has been demonstrated
(Abramovitch et al., 2004; Chen et al., 2005), its role in hypoxia-induced
retinal neovascularization is not known. Therefore, as CREB mediates
VEGFC-induced HRMVEC sprouting and tube formation, we next inves-
tigated the functional signiﬁcance of VEGFC–CREB axis in retinal neo-
vascularization. The observations that suppression of VEGFC levels
attenuates hypoxia-induced retinal EC proliferation, tip cell formation
and neovascularization suggest a role for VEGFC in pathological retinal
neovascularizaion. VEGFC has also been reported to play a role in devel-
opmental and tumor angiogenesis (De Palma et al., 2003; Ober et al.,
2004). Second, our ﬁndings show that hypoxia induces CREB activation
in retina in VEGFC-dependent manner and suppression of its levels
inhibits hypoxia-induced EC proliferation, tip cell formation and
neovascularization.
To elucidate themechanismsbywhichVEGFC–CREB axis plays a role
in vessel formation, we investigated the effect of VEGFC and hypoxia on
NOTCH signaling. Our in vitro and in vivo ﬁndings indicate that both
VEGFC and hypoxia stimulate DLL4–NOTCH1 signaling and these events
require the activation of CREB. In addition, hypoxia-induced DLL4–
NOTCH1 activation depends on VEGFC production. Furthermore, the
role of CREB in DLL4–NOTCH1 activation can be corroborated by the
observations that CREB is essential for VEGFC-induced DLL4 promoter
activity. It was noted that although VEGFA activated CREB in HRMVECs
it failed to enhanceDLL4 expression and cNOTCH1 production. Based on
these ﬁndings, it may be suggested that activation of CREB alone is not
sufﬁcient for DLL4 expression and that VEGFC besides CREB also triggers
the activation of additional signaling events, which in combinationwith
CREB are required for DLL4 expression and cNOTCH1 production. The
role of DLL4–NOTCH1 signaling in retinal neovascularization can be
supported by the ﬁndings that depletion of DLL4 or NOTCH1 led to a
decrease in VEGFC-induced proliferation, migration, tube formation
and sprouting in vitro and EC proliferation, tip cell formation and
neovacularization in vivo. The increase in avascular area in DLL4 and
NOTCH1-depleted retina adds additional line of evidence for the role
of NOTCH signaling in the regulation of tip cell formation. Indeed,
other studies have also reported that NOTCH signaling plays a role
in tip cell formation during angiogenesis (Hellstrom et al., 2007;
Tammela et al., 2011). In addition, a reduction in EC proliferation, tip
cells, tufts, and anastomoses in DLL4 or NOTCH1-depleted hypoxic ret-
ina support the observations of (Lobov et al. (2007, 2011) that genetic
deletion of DLL4 or administration of DLL4-Fc suppresses pathological
retinal neovascularization inOIRmodel. However, these authors report-
ed that inhibition of DLL4–NOTCH signaling results in enhanced
sprouting, which is contrary to our ﬁndings, as we did not observe
any increase in tip cell formation in DLL4 or NOTCH1-depleted retinas.
It should also be pointed out that many studies have demonstratedsing−2210 nt to+78 ntwas cloned and the nucleotide sequencewith CREB binding sites
ncatedDLL4 promoter encompassing from−605 nt to+78ntwere sub-cloned into pGL3
nsfected with empty vector or pGL3-hDLL4 (2.28 kb) or pGL3-hDLL4 (0.68 kb) promoter
vity was measured. C. Left panel: Nuclear extracts of control and various time periods of
g site at−193 nt as a Biotin-labeled probe. Right panel: Nuclear extracts of control and
anti-CREB antibodies. D. Control and various time periods of VEGFC (100 ng/ml)-treated
rs that amplify a 220 bp and a 106 bp DNA fragments surrounding the CREB-binding site
-bound DLL4 promoter. E. HRMVECs were transfected with empty vector or pGL3-hDLL4
mutated to CTC), growth-arrested, treated with and without VEGFC (100 ng/ml) for 4 h
hree independent experiments. The values represent Mean ± SD. * p b 0.01 vs control;
Fig. 6. CREB-mediated DLL4-NOTCH1 signaling is required for hypoxia-induced neovascularization. A. An equal amount of protein from normoxic and various time periods of hypoxic ret-
inal extracts were analyzed by Western blotting for the indicated proteins using their speciﬁc antibodies and normalized to β-tubulin. B. All the conditions were the same as in panel A
except that pups were administered intravitreally with 1 μg/0.5 μl/eye of scrambled, VEGFC or CREB siRNA at P10 and P11 and at P13 the retinas were isolated and tissue extracts were
prepared. An equal amount of protein from normoxic and hypoxic retinal extracts were analyzed by Western blotting for the indicated proteins using their speciﬁc antibodies and nor-
malized to β-tubulin. C. All the conditions were the same as in panel B except that pups were administered intravitreally with 1 μg/0.5 μl/eye of scrambled, DLL4 or NOTCH1 siRNA at
P12 and P13 and at P15 retinas were isolated and either tissue extracts were prepared and analyzed by Western blotting for DLL4 and NOTCH1 levels and normalized to β-tubulin or
cross-sectionsweremade, ﬁxed and stained by immunoﬂuorescence for CD31 and Ki67. D. Retinal EC proliferationwasmeasured by counting CD31- and Ki67-positive cells that extended
anterior to the inner limiting membrane per section (n = 6 eyes, 3 sections/eye). E. All the conditions were the same as in panel D except that at P17 retinas were isolated, stained with
isolectin B4 and ﬂatmounts weremade and examined for EC ﬁlopodia formation. F. All the conditionswere the same as in panel C except that the sectionswere stained for CD31, VEGFR3
andDAPI. G. All the conditionswere the same as in panel C except that pupswere administered intravitreallywith 1 μg/0.5 μl/eye of scrambled, DLL4 orNOTCH1 siRNA at P12, P13 and P15
and at P17 retinas were isolated, stained with isolectin B4, ﬂat mounts were made and examined for neovascularization. Retinal vascularization is shown in the ﬁrst row. Neovasculari-
zation is highlighted in red in the second row. The third row shows the selected rectangular areas of the images shown in the ﬁrst row under 10X magniﬁcation. H & I. Retinal neovascu-
larization (H) and avascular areas (I) were determined as described in “Materials and Methods.” The bar graphs represent quantitative analysis of 6 retinas. The values are presented as
Mean ± SD. * p b 0.01 vs normoxia, normoxia + control siRNA; ** p b 0.01 vs hypoxia + control siRNA. Scale bar represents 50 μm and 20 μm in panel C, far left column and far right
column, respectively, 20 μm in panels E & F and 300 μm and 50 μm in panel G, upper row and bottom row, respectively.
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Fig. 7.Conditional knockout of CREB in EC attenuates DLL4–NOTCH1 signaling and retinal neovascularization. A. Tamoxifen was given intraperitoneally to CREBﬂ/ﬂ:Cdh5-CreERT2, and
CREBﬂ/−:Cdh5-CreERT2 pups on P10 and P11, when the pups were under hyperoxia and at P13 the retinas were isolated from WT (both from normoxia and hypoxia), CREBiΔEC, and
CREBﬂ/−:Cdh5-CreERT2T/− pups, and extracts were prepared and an equal amount of protein from each group was analyzed by Western blotting for CREB using its speciﬁc antibody
and normalized to β-tubulin. B. All the conditions were the same as in panel A except that the retinal extracts from WT, CREBiΔEC pups were analyzed by Western blotting for DLL4,
NOTCH1 and CREB levels using their speciﬁc antibodies and normalized to β-tubulin. C & D. WT and CREBiΔEC mice pups after exposure to 75% oxygen from P7 to P12 were returned
to normoxia to develop the relative hypoxia. At P15, the retinas were isolated, cross-sections were made and stained by immunoﬂuorescence for CD31 and Ki67 (C) and cells pos-
itive for both CD31 and Ki67 were counted (D). E & F. All the conditions were the same as in panel C except that at P17 the retinas were isolated, stained with isolectin B4 and ﬂat
mounts were made and examined either for EC ﬁlopodia formation or neovascularization. In panel F, retinal vascularization is shown in the ﬁrst column. Neovascularization is
highlighted in red in the second column. The third column shows the selected rectangular areas of the images shown in the ﬁrst column under 10X magniﬁcation. G & H. Retinal
neovascularization (G) and avascular areas (H) were determined as described in “Materials and Methods.” The bar graphs represent quantitative analysis of 6 retinas. The values are
presented as Mean ± SD. * p b 0.01 vs WT. Scale bar represents 50 μm and 20 μm in panel C, far left column and far right column, respectively, 20 μm in panel E and 300 μm and
50 μm in panel F, far left column and far right column, respectively.
1780 N.K. Singh et al. / EBioMedicine 2 (2015) 1767–1784that inhibition of DLL4 or NOTCH1 levels results in excessive sprouting
(Phng and Gerhardt, 2009) but reduces tumor growth (Noguera-Troise
et al., 2006; Ridgway et al., 2006). It should also be pointed out
that many reports show that the DLL4–NOTCH1 signaling negatively
regulates EC proliferation, migration and tip cell formation while
enhancing stalk cells (Hellstrom et al., 2007; Williams et al., 2006). On
the other hand, our results show that the DLL4–NOTCH1 signaling
enhances EC proliferation, migration and tip cell formation bothFig. 8. p38MAPKβmediates VEGFC-induced angiogenic events. A. An equal amount of protein from
Western blotting for pJNK1 and pp38MAPK levels using their phospho-speciﬁc antibodies an
dnp38MAPKβ (p38β) (40 moi), growth-arrested, treated with and without VEGFC (100 ng/ml) f
speciﬁc antibodies and the blot was sequentially reprobed for CREB, JNK1, p38MAPK and β-tubulin
duced with Ad-GFP or Ad-dnp38β (40 moi), growth-arrested, treated with and without VEGFC (1
using their speciﬁc antibodies and the blotwas sequentially reprobed for p38β andβ-tubulin to sh
or Ad-dnp38β (40 moi), growth-arrested and subjected to DNA synthesis (D), migration (E), tube
dependent experiments. The values are presented as Mean ± SD. * p b 0.01 vs control; ** p b 0.0in vitro in cell culture system and in vivo in hypoxic retina. A recent
study also reported that the DLL4–NOTCH1 signaling via modulating
TGFβ expression enhances tumor cell growth (Ohnuki et al., 2014),
which is in line with our ﬁndings on the role of DLL4–NOTCH1 signaling
in cell proliferation.
In order to validate the link between CREB andNOTCH in the regula-
tion of pathological retinal angiogenesis, we employed inducible
endothelial-speciﬁc CREB (CREBiΔEC) knockout mice. First, EC-speciﬁccontrol and various time periods of VEGFC (100 ng/ml)-treatedHRMVECswere analyzed by
d normalized to their total levels. B. Cells were transduced with Ad-GFP, Ad-JNK1 or Ad-
or 10 min and cell extracts were prepared and analyzed for pCREB levels using its phospho-
levels to show the over expression of dnJNK1, dnp38β or normalization. C. Cells were trans-
00 ng/ml) for 2 h and cell extracts were prepared and analyzed for DLL4 or cNOTCH1 levels
ow the over expression of dnp38β or normalization. D–G. Cellswere transducedwith Ad-GFP
formation (F) or sprouting assay (G). The bar graphs represent quantitative analysis of 3 in-
1 vs control siRNA + VEGFC. Scale bar represents 50 μm in panel E.
1781N.K. Singh et al. / EBioMedicine 2 (2015) 1767–1784deletion of CREB in CREBiΔEC mice pups by tamoxifen led to decreased
DLL4 expression and cNOTCH1production in the hypoxic retina as com-
pared toWTmice pups, a ﬁnding that shows the requirement of CREB inthe regulation of DLL4–NOTCH1 signaling. Second, EC-speciﬁc deletion
of CREB in CREBiΔEC mice pups also caused a decrease in ectopic growth
of neovascular tufts and anastomoses with an increase in avascular area
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tions attest that CREB–DLL4–NOTCH1 signaling plays a major role in
pathological retinal neovascularization. Many reports have shown that
MAPKs play a role in the activation of CREB in response to a variety of
cues (Deak et al., 1998; Xing et al., 1998). In this context, our results re-
veal that p38MAPKβ mediates CREB phosphorylation in response to
VEGFC in HRMVECs and hypoxia in the retina. In addition, activation
of p38MAPKβ is required for VEGFC-induced DLL4 expression and
cNOTCH1 production in HRMVECs facilitating their proliferation,migra-
tion, sprouting and tubulogenesis. Similarly, hypoxia induced p38MAPK
activation in a manner that is dependent on VEGFC production and
down regulation of p38MAPKβ levels attenuated hypoxia-induced
CREB phosphorylation, DLL4 expression and cNOTCH1 production and,
thereby, reducing retinal EC proliferation, tip cell formation, and neo-
vascularization. Based on these ﬁndings, it may be suggested that
p38MAPKβ via activation of CREB triggers DLL4–NOTCH1 signaling in
enhancing EC proliferation, tip cell formation and retinal neovasculari-
zation. Retinal neovascularization is a leading cause of blindness in con-
ditions such as diabetic retinopathy and retinopathy of pre-maturity.
Presently, although anti-VEGFA therapy appears to be the major treat-
ment for these ocular pathologies, such treatments have met with lim-
itations (Arevalo et al., 2008; Kuiper et al., 2008). In this aspect, the
present ﬁndings identify p38MAPKβ and CREB as potential targets in
the development of therapeutic compounds in the amelioration of path-
ological retinal neovascularization. Based on the present and previous
observations, therapies that target both VEGFA and VEGFC might also
prove to be more efﬁcacious in treating retinopathies.
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